Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of included studies

From: Does Alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women

Study (reference) Sample (ALN*/ control) and duration Inclusion criteria Age (years) (SD‡) Percentage prevalent vertebral fractures (VF, %) Intervention/ Control Blinding, randomization Loss to follow-up or withdrew from study (n/N) (%)
Orwoll 2000 [11] 146/95 (2 years) Men with BMD† T-score = -2 at femoral neck and T-score = -1 at the lumbar spine;
OR Men with T-score = -1 at the femoral neck and at least one vertebral or osteoporotic fracture
ALN:
Mean age 63 (13)
49% VF
Control: Mean age 63 (12)
52% VF
ALN*: 10 mg + 500 mg Calcium + 400–450 IU Vitamin D
Control: 500 mg Calcium + 400–450 IU Vitamin D
- Double-blind
- Radiologists reading vertebral x-rays blinded to intervention
-Method of randomization unclear
38/241 (15.8%)
Ringe 2004 [12] 68/66 (3 years) Men with BMD† T-score = -2.5 at femoral neck or lumbar spine, excluding hypogonadal men ALN*:
Mean age 52.7 (11.1)
54% VF
Control:
Mean age 53.3 (10.9)
53% VF
ALN*: 10 mg + 500 mg Calcium Control: 500 mg Calcium + 1 μg alfacalcidiol - Open-label
- Radiologists reading vertebral x-rays blinded to intervention
-Method of randomization unclear
16/134 (11.9%)
  1. *ALN, alendronate (daily dose)
  2. \dagBMD, bone mineral density measurement by dual X-ray absorptiometry, compared to young adult male peak bone mass
  3. \ddagSD, Standard deviation